BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26964772)

  • 1. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
    Costa DB; Jorge SE; Moran JP; Freed JA; Zerillo JA; Huberman MS; Kobayashi SS
    J Thorac Oncol; 2016 Jun; 11(6):918-23. PubMed ID: 26964772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
    Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
    J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Potential of Afatinib for Cancers with
    Yamamoto H; Toyooka S; Ninomiya T; Matsumoto S; Kanai M; Tomida S; Kiura K; Muto M; Suzawa K; Desmeules P; Kris MG; Li BT; Ladanyi M
    Oncologist; 2018 Feb; 23(2):150-154. PubMed ID: 29146616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poziotinib in Non-Small-Cell Lung Cancer Harboring
    Le X; Cornelissen R; Garassino M; Clarke JM; Tchekmedyian N; Goldman JW; Leu SY; Bhat G; Lebel F; Heymach JV; Socinski MA
    J Clin Oncol; 2022 Mar; 40(7):710-718. PubMed ID: 34843401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
    Peters S; Curioni-Fontecedro A; Nechushtan H; Shih JY; Liao WY; Gautschi O; Spataro V; Unk M; Yang JC; Lorence RM; Carrière P; Cseh A; Chang GC
    J Thorac Oncol; 2018 Dec; 13(12):1897-1905. PubMed ID: 30096481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
    Jia Y; Ali SM; Saad S; Chan CA; Miller VA; Halmos B
    Cancer Biol Ther; 2014 Aug; 15(8):970-4. PubMed ID: 24835218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
    Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
    Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
    Chuang JC; Stehr H; Liang Y; Das M; Huang J; Diehn M; Wakelee HA; Neal JW
    J Thorac Oncol; 2017 May; 12(5):833-842. PubMed ID: 28167203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
    Lai WV; Lebas L; Barnes TA; Milia J; Ni A; Gautschi O; Peters S; Ferrara R; Plodkowski AJ; Kavanagh J; Sabari JK; Clarke SJ; Pavlakis N; Drilon A; Rudin CM; Arcila ME; Leighl NB; Shepherd FA; Kris MG; Mazières J; Li BT
    Eur J Cancer; 2019 Mar; 109():28-35. PubMed ID: 30685684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
    J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
    Li BT; Lee A; O'Toole S; Cooper W; Yu B; Chaft JE; Arcila ME; Kris MG; Pavlakis N
    Lung Cancer; 2015 Dec; 90(3):617-9. PubMed ID: 26559459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
    Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
    Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
    Wada Y; Koyama S; Kuraishi H; Miyahara T; Yoshiike F; Agatsuma T; Yamamoto R; Ono Y; Suzuki T; Hachiya T; Gomi D; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2016 Nov; 54(6):462-467. PubMed ID: 27886858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
    J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
    Dziadziuszko R; Smit EF; Dafni U; Wolf J; Wasąg B; Biernat W; Finn SP; Kammler R; Tsourti Z; Rabaglio M; Ruepp B; Roschitzki-Voser H; Stahel RA; Felip E; Peters S
    J Thorac Oncol; 2019 Jun; 14(6):1086-1094. PubMed ID: 30825613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
    Arrieta O; Cruz-Rico G; Soto-Perez-de-Celis E; Ramírez-Tirado LA; Caballe-Perez E; Martínez-Hernández JN; Martinez-Alvarez I; Soca-Chafre G; Macedo-Pérez EO; Astudillo-de la Vega H
    Target Oncol; 2016 Oct; 11(5):619-629. PubMed ID: 27033062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
    Yang JC; Shih JY; Su WC; Hsia TC; Tsai CM; Ou SH; Yu CJ; Chang GC; Ho CL; Sequist LV; Dudek AZ; Shahidi M; Cong XJ; Lorence RM; Yang PC; Miller VA
    Lancet Oncol; 2012 May; 13(5):539-48. PubMed ID: 22452895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.